NASDAQ, BIIB - Biogen Inc
Biogen Idec creates new standards of care in therapeutic areas with high unmet
medical needs. Biogen Idec is a global leader in the development, manufacturing,
and commercialization of innovative therapies. Patients in more than 90
countries benefit from Biogen Idec?s significant products that address diseases
such as multiple sclerosis, lymphoma and rheumatoid arthritis. We currently have
four products:
AVONEX? (interferon beta-1a)
AVONEX is approved worldwide for the treatment of relapsing forms of multiple
sclerosis, or MS, and is the most prescribed therapeutic product in MS
worldwide. Globally over 135,000 patients use AVONEX.
RITUXAN? (rituximab)
RITUXAN is approved worldwide for the treatment of relapsed or refractory
low-grade or follicular, CD20-positive, B-cell non-Hodgkin?s lymphomas, or
B-cell NHLs. The U.S. ...
Read SEC Filing on NASDAQ.com »